Trillium reports Phase I data for TTI-621 in DLBCL

By Allison Johnson | Jan 5, 2018 | 9:52 PM GMT

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported data from 18 evaluable patients with diffuse large B cell lymphoma (DLBCL) in the dose-expansion

Read the full 215 word article

How to gain access

Continue reading with a
two-week free trial.